ADVERSE REACTIONS SECTION.


ADVERSE REACTIONS. No side effects or manifestations not seen with either compound alone have been reported with the administration of Chlordiazepoxide HCl/Clidinium Bromide. However, the possibility of untoward effects which may be seen with either of these two compounds cannot be excluded.When chlordiazepoxide hydrochloride has been used alone the necessity of discontinuing therapy because of undesirable effects has been rare. Drowsiness, ataxia and confusion have been reported in some patients -- particularly the elderly and debilitated. While these effects can be avoided in almost all instances by proper dosage adjustment, they have occasionally been observed at the lower dosage ranges. In few instances syncope has been reported.Other adverse reactions reported during therapy with chlordiazepoxide hydrochloride include isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation, extrapyramidal symptoms, as well as increased and decreased libido. Such side effects have been infrequent and are generally controlled with reduction of dosage. Changes in EEG patterns (low-voltage fast activity) have been observed in patients during and after chlordiazepoxide hydrochloride treatment.Blood dyscrasias, including agranulocytosis, jaundice and hepatic dysfunction have occasionally been reported during therapy with chlordiazepoxide hydrochloride. When chlordiazepoxide hydrochloride treatment is protracted, periodic blood counts and liver function tests are advisable.Adverse effects reported with use of Chlordiazepoxide HCl/Clidinium Bromide are those typical of anticolinergic agents, ie, dryness of the mouth, blurring of vision, urinary hesitancy and constipation. Constipation has occurred most often when Chlordiazepoxide HCl/Clidinium Bromide therapy has been combined with other spasmolytic agents and/or low residue diet.

CLINICAL PHARMACOLOGY SECTION.


ANIMAL PHARMACOLOGY. Chlordiazepoxide hydrochloride has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses.Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide hydrochloride revealed taming action with the elimination of fear and aggression. The taming effect of chlordiazepoxide hydrochloride was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals.The oral LD50 of single doses of chlordiazepoxide hydrochloride, calculated according to the method of Miller and Tainter, is 720 +- 51 mg/kg as determined in mice observed over period of days following dosage.Clidinium bromide is an effective anticholinergic agent with activity approximating that of atropine sulfate against acetylcholine-induced spasms in isolated intestinal strips. On oral administration in mice it proved an effective antisialagogue in preventing pilocarpine-induced salivation. Spontaneous intestinal motility in both rats and dogs is reduced following oral dosing with 0.1 to 0.25 mg/kg. Potent cholinergic ganglionic blocking effects (vagal) are produced with intravenous usage in anesthetized dogs.Oral doses of 2.5 mg/kg to dogs produced signs of nasal dryness and slight pupillary dilation. In two other species, monkeys and rabbits, doses of mg/kg, po, given three times daily for days did not produce apparent secretory or visual changes.The oral LD50 of single doses of clidinium bromide is 860 +- 57 mg/kg as determined in mice observed over period of days following dosage; the calculations were made according to the method of Miller and Tainter.. Effects on Reproduction. Reproduction studies in rats fed chlordiazepoxide hydrochloride, 10, 20 and 80 mg/kg daily, and bred through one or two matings showed no congenital anomalies, nor were there adverse effects on lactation of the dams or growth of the newborn. However, in another study at 100 mg/kg daily there was noted significant decrease in the fertilization rate and marked decrease in the viability and body weight of offspring which may be attributable to sedative activity, thus resulting in lack of interest in mating and lessened maternal nursing and care of the young. One neonate in each of the first and second matings in the rat reproduction study at the 100 mg/kg dose exhibited major skeletal defects. Further studies are in progress to determine the significance of these findings.Two series of reproduction experiments with clidinium bromide were carried out in rats, employing dosages of 2.5 and 10 mg/kg daily in each experiment. In the first experiment clidinium bromide was administered for 9-week interval prior to mating; no untoward effect on fertilization or gestation was noted. The offspring were taken by caesarean section and did not show significant incidence of congenital anomalies when compared to control animals. In the second experiment adult animals were given clidinium bromide for 10 days prior to and through two mating cycles. No significant effects were observed on fertility, gestation, viability of offspring or lactation, as compared to control animals, nor was there significant incidence of congenital anomalies in the offspring derived from these experiments.A reproduction study of Chlordiazepoxide HCl/Clidinium Bromide was carried out in rats through two successive matings. Oral daily doses were administered in two concentrations: 2.5 mg/kg chlordiazepoxide hydrochloride with 1.25 mg/kg clidinium bromide or 25 mg/kg chlordiazepoxide hydrochloride with 12.5 mg/kg clidinium bromide. In the first mating no significant differences were noted between the control or the treated groups, with the exception of slight decrease in the number of animals surviving during lactation among those receiving the highest dosage. As with all anticholinergic drugs, an inhibiting effect on lactation may occur. In the second mating similar results were obtained except for slight decrease in the number of pregnant females and in the percentage of offspring surviving until weaning. No congenital anomalies were observed in both matings in either the control or treated groups. Additional animal reproduction studies are in progress.

CONTRAINDICATIONS SECTION.


CONTRAINDICATIONS. Chlordiazepoxide HCl/Clidinium Bromide is contraindicated in the presence of glaucoma (since the anticholinergic component may produce some degree of mydriasis) and in patients with prostatic hypertrophy and benign bladder neck obstruction. It is contraindicated in patients with known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide.

DESCRIPTION SECTION.


DESCRIPTION. Chlordiazepoxide HCl/Clidinium Bromide combines in single capsule formulation the antianxiety action of chlordiazepoxide hydrochloride and the anticholinergic/spasmolytic effects of clidinium bromide, both exclusive developments of Roche research.Each Chlordiazepoxide HCl/Clidinium Bromide capsule contains mg chlordiazepoxide hydrochloride and 2.5 mg clidinium bromide. Each capsule also contains corn starch, lactose and talc. Gelatin capsule shells may contain methyl and propyl parabens and potassium sorbate, with the following dye systems: D&C Yellow No. 10 and either FD&C Blue No. or FD&C Green No. 3.Chlordiazepoxide hydrochloride is versatile, therapeutic agent of proven value for the relief of anxiety and tension. It is indicated when anxiety, tension or apprehension are significant components of the clinical profile. It is among the safer of the effective psychopharmacologic compounds.Chlordiazepoxide hydrochloride is 7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine 4-oxide hydrochloride. colorless, crystalline substance, it is soluble in water. It is unstable in solution and the powder must be protected from light. The molecular weight is 336.22. The structural formula of chlordiazepoxide hydrochloride is as follows:Clidinium bromide is synthetic anticholinergic agent which has been shown in experimental and clinical studies to have pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. Structurally clidinium bromide is:. Chmical Structure. Chmical Structure.

DOSAGE & ADMINISTRATION SECTION.


DOSAGE AND ADMINISTRATION. Because of the varied individual responses to tranquilizers and anticholinergics, the optimum dosage of Chlordiazepoxide HCl/Clidinium Bromide varies with the diagnosis and response of the individual patient. The dosage, therefore, should be individualized for maximum beneficial effects. The usual maintenance dose is or capsules, or times day administered before meals and at bedtime.. Geriatric Dosing. Dosage should be limited to the smallest effective amount to preclude the development of ataxia, oversedation or confusion. The initial dose should not exceed Chlordiazepoxide HCl/Clidinium Bromide capsules per day, to be increased gradually as needed and tolerated.

DRUG ABUSE AND DEPENDENCE SECTION.


DRUG ABUSE AND DEPENDENCE. Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of chlordiazepoxide. The more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. Generally milder withdrawal symptoms (eg, dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and gradual dosage tapering schedule followed. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving chlordiazepoxide or other psychotropic agents because of the predisposition of such patients to habituation and dependence.

GERIATRIC USE SECTION.


Geriatric Use. Geriatric subjects may be particularly prone to experiencing drowsiness, ataxia and confusion while receiving Chlordiazepoxide HCl/Clidinium Bromide. These effects can usually be avoided with proper dosage adjustment, although they have occasionally been observed even at the lower dosage ranges. Dosing in geriatric subjects should be initiated cautiously (no more than capsules per day) and increased gradually if needed and tolerated (see DOSAGE AND ADMINISTRATION). Chlordiazepoxide HCl/Clidinium Bromide is contraindicated in the presence of glaucoma, prostatic hypertrophy and benign bladder neck obstruction (see CONTRAINDICATIONS).

HOW SUPPLIED SECTION.


HOW SUPPLIED. Product: 50090-1528NDC: 50090-1528-0 30 CAPSULE in BOTTLE.

INDICATIONS & USAGE SECTION.


INDICATIONS AND USAGE. Based on review of this drug by the National Academy of Sciences -- National Research Council and/or other information, FDA has classified the indications as follows:Possibly effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.Final classification of the less-than-effective indications requires further investigation.

INFORMATION FOR PATIENTS SECTION.


Information for Patients. To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical dependence, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.

OVERDOSAGE SECTION.


OVERDOSAGE. Manifestations of chlordiazepoxide hydrochloride overdosage include somnolence, confusion, coma and diminished reflexes. Respiration, pulse and blood pressure should be monitored, as in all cases of drug overdosage, although, in general, these effects have been minimal following chlordiazepoxide hydrochloride overdosage.While the signs and symptoms of Chlordiazepoxide HCl/Clidinium Bromide overdosage may be produced by either of its components, usually such symptoms will be overshadowed by the anticholinergic actions of clidinium bromide. The symptoms of overdosage of clidinium bromide are excessive dryness of mouth, blurring of vision, urinary hesitancy and constipation.General supportive measures should be employed, along with immediate gastric lavage. Administer physostigmine 0.5 to mg at rate of no more than mg per minute. This may be repeated in to mg doses if arrhythmias, convulsions or deep coma recur. Intravenous fluids should be administered and an adequate airway maintained. Hypotension may be combated by the use of levarterenol or metaraminol. Methylphenidate or caffeine and sodium benzoate may be given to combat CNS-depressive effects. Dialysis is of limited value. Should excitation occur, barbiturates should not be used. As with the management of intentional overdosage with any drug, it should be borne in mind that multiple agents may have been ingested.Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines (see DRUG ABUSE AND DEPENDENCE section).

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.


Chlordiazepoxide Hydrochloride and Clidinium Bromide. Label Image.

PEDIATRIC USE SECTION.


Pediatric Use. Safety and effectiveness in pediatric patients have not been established.

PRECAUTIONS SECTION.


PRECAUTIONS. In debilitated patients, it is recommended that the dosage be limited to the smallest effective amount to preclude the development of ataxia, oversedation or confusion (not more than Chlordiazepoxide HCl/Clidinium Bromide capsules per day initially, to be increased gradually as needed and tolerated). In general, the concomitant administration of Chlordiazepoxide HCl/Clidinium Bromide and other psychotropic agents is not recommended. If such combination therapy seems indicated, careful consideration should be given to the pharmacology of the agents to be employed -- particularly when the known potentiating compounds such as the MAO inhibitors and phenothiazines are to be used. The usual precautions in treating patients with impaired renal or hepatic function should be observed.Paradoxical reactions to chlordiazepoxide hydrochloride, eg, exctextent, stimulation and acute rage, have been reported in psychiatric patients and should be watched for during Chlordiazepoxide HCl/Clidinium Bromide therapy. The usual precautions are indicated when chlordiazepoxide hydrochloride is used in the treatment of anxiety states where there is any evidence of impending depression; it should be borne in mind that suicidal tendencies may be present and protective measures may be necessary. Although clinical studies have not established cause and effect relationship, physicians should be aware that variable effects on blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide hydrochloride.. Information for Patients. To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical dependence, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.. Pediatric Use. Safety and effectiveness in pediatric patients have not been established.. Geriatric Use. Geriatric subjects may be particularly prone to experiencing drowsiness, ataxia and confusion while receiving Chlordiazepoxide HCl/Clidinium Bromide. These effects can usually be avoided with proper dosage adjustment, although they have occasionally been observed even at the lower dosage ranges. Dosing in geriatric subjects should be initiated cautiously (no more than capsules per day) and increased gradually if needed and tolerated (see DOSAGE AND ADMINISTRATION). Chlordiazepoxide HCl/Clidinium Bromide is contraindicated in the presence of glaucoma, prostatic hypertrophy and benign bladder neck obstruction (see CONTRAINDICATIONS).

PREGNULLNCY SECTION.


Usage in Pregnancy. An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam and meprobamate) during the first trimester of pregnancy has been suggested in several studies. Because use of these drugs is rarely matter of urgency, their use during this period should almost always be avoided. The possibility that woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physicians about the desirability of discontinuing the drug.As with all anticholinergic drugs, an inhibiting effect on lactation may occur (see Animal Pharmacology).

SPL MEDGUIDE SECTION.


Medication Guide LIBRAX (lee braks)(chlordiazepoxide HCl and clidinium bromide) capsulesWhat is the most important information should know about LibraxoDo not stop taking Librax without first talking to your healthcare provider. Stopping Librax suddenly can cause serious side effects.oTaking Librax with opioid medicines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death.oDo not drive, operate heavy machinery, or do other dangerous activities until you know how Librax affects you.oDo not drink alcohol or take other drugs that may make you sleepy or dizzy while taking Librax without first talking to your healthcare provider. When taken with alcohol or drugs that cause sleepiness or dizziness, Librax may make your sleepiness or dizziness much worse.oLibrax can cause abuse and dependence.oDo not stop taking Librax all of sudden. Stopping Librax suddenly can cause seizures, shaking, stomach and muscle cramps, vomiting and sweating.oPhysical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the differences between physical dependence and drug addiction.What is LibraxoLibrax is prescription medicine that is used with other therapies for the treatment of:ostomach (peptic) ulcersoirritable bowel syndrome (IBS)oinflammation of the colon called acute enterocolitisoLibrax contains the medicines chlordiazepoxide HCl and clidinium bromide.oLibrax can be abused or lead to dependence. Keep Librax in safe place to prevent misuse and abuse. Selling or giving away Librax may harm others. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs.oIt is not known if Librax is safe and effective in children.Do not take Librax if you:ohave glaucomaohave an enlarged prostateohave blockage of your bladder that causes problems with urinationoare allergic to chlordiazepoxide hydrochloride or clidinium bromideBefore you take Librax, tell your healthcare provider about all of your medical conditions, including if you:ohave eye problemsohave problems urinating or emptying your bladderohave coordination problemsohave kidney or liver problemsohave history of depression, mental illness, or suicidal thoughtsohave history of drug or alcohol abuse or addictionohave bleeding problemsoare pregnant or plan to become pregnant. Librax may harm your unborn baby. Avoid taking Librax during the first trimester of pregnancy. Tell your healthcare provider right away if you become pregnant during treatment with Librax.oare breastfeeding or plan to breastfeed. Librax may pass through your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take Librax. Librax may decrease the amount of breast milk your body makes.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.Taking Librax with certain other medicines can cause side effects or affect how well Librax or the other medicines work.Do not start or stop other medicines without talking to your healthcare provider.Especially tell your healthcare provider if you:otake monoamine oxidase inhibitor (MAOI) medicine or an anti-psychotic medicine called phenothiazine.How should take LibraxoTake Librax exactly as your healthcare provider tells you to take it.oYour healthcare provider may change your dose of Librax if needed. Do not change your dose of Librax or suddenly stop taking Librax without talking with your healthcare provider.oIf you take too much Librax, call your healthcare provider or go to the nearest hospital emergency room right away.What are the possible side effects of LibraxLibrax may cause serious side effects, including: See What is the most important information should know about LibraxThe most common side effects of Librax include:odry mouthoblurred visiononauseaoconstipationoskin problemsoswellingoirregular menstrual (periods) cyclesoincrease and decreased desire for sex (libido)oproblems starting to urinateodrowsiness, coordination problems, and confusion may happen, especially in people who are elderly or weakThese are not all the possible side effects of Librax.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.How should store LibraxoStore Librax at room temperature 77F (25C).oKeep Librax and all medicines out of the reach of children.General information about the safe and effective use of Librax.Medicines are sometimes prescribed for purposes other than those listed in Medication Guide. Do not use Librax for condition for which it was not prescribed. Do not give Librax to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Librax that is written for health professionals.What are the ingredients in LibraxActive ingredient: chlordiazepoxide hydrochloride and clidinium bromideInactive ingredients: corn starch, lactose and talc. Gelatin capsule shells may contain methyl and propyl parabens and potassium sorbate, with the following dye systems: D&C Yellow No. 10 and either FD&C Blue No.1 or FD&C Green No. 3.Manufactured in Canada by: Valeant Pharmaceuticals International, Inc. Steinbach, MB R5G 1Z7 CanadaManufactured for: Valeant Pharmaceuticals North America LLC Bridgewater, NJ 08807 USALibrax is trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.(C)Valeant Pharmaceuticals North America LLC For more information, go to www.valeant.com or contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576This Medication Guide has been approved by the U.S. Food and Drug AdministrationIssued: 01/2017. oDo not stop taking Librax without first talking to your healthcare provider. Stopping Librax suddenly can cause serious side effects.. oTaking Librax with opioid medicines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death.. oDo not drive, operate heavy machinery, or do other dangerous activities until you know how Librax affects you.. oDo not drink alcohol or take other drugs that may make you sleepy or dizzy while taking Librax without first talking to your healthcare provider. When taken with alcohol or drugs that cause sleepiness or dizziness, Librax may make your sleepiness or dizziness much worse.. oLibrax can cause abuse and dependence.. oDo not stop taking Librax all of sudden. Stopping Librax suddenly can cause seizures, shaking, stomach and muscle cramps, vomiting and sweating.. oPhysical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the differences between physical dependence and drug addiction.. oLibrax is prescription medicine that is used with other therapies for the treatment of:. ostomach (peptic) ulcers. oirritable bowel syndrome (IBS). oinflammation of the colon called acute enterocolitis. oLibrax contains the medicines chlordiazepoxide HCl and clidinium bromide.. oLibrax can be abused or lead to dependence. Keep Librax in safe place to prevent misuse and abuse. Selling or giving away Librax may harm others. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs.. oIt is not known if Librax is safe and effective in children.. ohave glaucoma. ohave an enlarged prostate. ohave blockage of your bladder that causes problems with urination. oare allergic to chlordiazepoxide hydrochloride or clidinium bromide. ohave eye problems. ohave problems urinating or emptying your bladder. ohave coordination problems. ohave kidney or liver problems. ohave history of depression, mental illness, or suicidal thoughts. ohave history of drug or alcohol abuse or addiction. ohave bleeding problems. oare pregnant or plan to become pregnant. Librax may harm your unborn baby. Avoid taking Librax during the first trimester of pregnancy. Tell your healthcare provider right away if you become pregnant during treatment with Librax.. oare breastfeeding or plan to breastfeed. Librax may pass through your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take Librax. Librax may decrease the amount of breast milk your body makes.. otake monoamine oxidase inhibitor (MAOI) medicine or an anti-psychotic medicine called phenothiazine.. oTake Librax exactly as your healthcare provider tells you to take it.. oYour healthcare provider may change your dose of Librax if needed. Do not change your dose of Librax or suddenly stop taking Librax without talking with your healthcare provider.. oIf you take too much Librax, call your healthcare provider or go to the nearest hospital emergency room right away.. odry mouth. oblurred vision. onausea. oconstipation. oskin problems. oswelling. oirregular menstrual (periods) cycles. oincrease and decreased desire for sex (libido). oproblems starting to urinate. odrowsiness, coordination problems, and confusion may happen, especially in people who are elderly or weak. oStore Librax at room temperature 77F (25C).. oKeep Librax and all medicines out of the reach of children.

SPL UNCLASSIFIED SECTION.


to control emotionaland somatic factorsin gastrointestinal disorders.

WARNINGS SECTION.


WARNINGS. As in the case of other preparations containing CNS-acting drugs, patients receiving Chlordiazepoxide HCl/Clidinium Bromide should be cautioned about possible combined effects with alcohol and other CNS depressants. For the same reason, they should be cautioned against hazardous occupations requiring complete mental alertness such as operating machinery or driving motor vehicle.. Usage in Pregnancy. An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam and meprobamate) during the first trimester of pregnancy has been suggested in several studies. Because use of these drugs is rarely matter of urgency, their use during this period should almost always be avoided. The possibility that woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physicians about the desirability of discontinuing the drug.As with all anticholinergic drugs, an inhibiting effect on lactation may occur (see Animal Pharmacology).